Other Affiliations
and Conflict Disclosure
DirectorAnnual Reviews, Global Coalition for Adaptive Research (GCAR), n-Lorem Foundation, Vesalius TherapeuticsAdvisor toAACR Oncology Development Fund, AIF Global, Apricity Health, Aracari Bio, Aurora Therapeutics, AUTS2 Research Collaborative, BrightEdge Impact Fund, Cancer Focus Fund, Ellison Medical Institute, Gondola Bio, Health at Scale, Khora Therapeutics, MIT Proto Ventures, Ride Therapeutics, Roivant Social Ventures, Sakura Health, Swiss Finance Institute, Thalēs, Think Therapeutics, xCuresCo-founderQLS TechnologiesCo-founder and AdvisorQuantile Health, Rutherford Energy VenturesCo-founder and ChairmanENRAPT, QLS AdvisorsCo-founder and DirectorBridgeBio Pharma, TechTransferase, Uncommon CuresPersonal investments inACISM, Apricity Health, Aracari Bio, BillionToOne, BridgeBio Pharma, Fidelity Select Biotech Fund, Khora Therapeutics, Ladder Tx, LS Polaris Innovation Fund, Macrocosm LLC, Medallion, MPM Capital Fund, Nautilus Biotech, Nurture Genomics, Peer Collective, Polaris Innovation Fund II, Proactive Labs, PsiThera, Quantile Health, Ride Therapeutics, Sakura Health, Stratus Therapeutics, SURGE Therapeutics, Uncommon Cures, Waypoint Bio
During the most recent six-year period, Lo has received speaking/consulting fees, honoraria, or other forms of compensation from: AbCellera, AlphaSimplex, Annual Reviews, Apricity Health, Aracari Bio, Atomwise, BridgeBio, CME, Enable Medicines, JOIM, Lazard, MIT, New Frontier Advisors, Oppenheimer, Princeton University Press, Q Group, QLS Advisors, Quantile Health, Roivant Sciences, Rutherford Energy Ventures, Saliogen, Stern Speakers, Swiss Finance Institute, Think Tx, Vesalius, and WW Norton. In addition, the MIT Laboratory for Financial Engineering (LFE), for which Lo serves as director, has received funding support from the Critical Path Institute, J.P. Morgan Asset & Wealth Management, Schmidt Futures, and Wellcome Leap. [Last updated: 13 June 2026]
